|
Two Industry Executives Appointed to Realigned Advisory Board |
 |
Vienna, Europe, September 2, 2010 – EUCODIS Bioscience, a developer and manufacturer of customized enzymes announced today the appointment of two seasoned biotechnology executives to its Advisory Board. The new appointees are Dr. David Rozzell, founder of BioCatalytics (now Codexis) and currently CEO of Solidus Biosciences, and Dr. Ulf Bethke, COO of Miltenyi Biotec. Dr. Thomas Moser, Pontis Capital, and Harald Schuerz, Wiener Wachstumsfonds, will continue to serve on the realigned Advisory Board.
With its current members, EUCODIS Bioscience’s Advisory Board will focus on providing guidance and advice in the areas of strategy, market and organization, strengthening the skills and experience of EUCODIS Bioscience’s management team.
“I am extremely pleased to welcome two distinguished executives of the biotechnology industry to our Advisory Board”, said Thomas Fischer, CEO EUCODIS Bioscience. “Dr. Rozzell as a successful founder and entrepreneur in the enzyme industry, and Dr. Bethke with his entrepreneurial mindset and his track record in biotechnology manufacturing and operations, bring to EUCODIS Bioscience a wealth of hands-on experience and operational knowledge. Having these seasoned executives on our Advisory Board will be a tremendous asset to the Company as our customer base is growing rapidly. We will continue to expand our portfolio, and are aggressively addressing new business opportunities in the pharmaceutical, bioproducts, cosmetics, and other industries.”
Dr. David Rozzell is President and CEO of Solidus Biosciences, a company providing research and analytical services to the pharmaceutical and cosmetics industry, enhancing their development productivity. Prior to joining Solidus as CEO, he was the Founder and CEO of enzyme developer BioCatalytics, which he grew to a leader in its field until the company was successfully sold to Codexis in 2007. Before founding BioCatalytics, Dr. Rozzell was President and COO of Exogene.
Dr. Ulf Bethke is Chief Operating Officer of Miltenyi Biotec, one of Germany’s most successful biotechnology companies. Before joining Miltenyi Biotec in 1994, he was responsible for the development and production of therapeutic monoclonal antibodies at Biotest, a German pharmaceutical company.
Dr. Thomas Moser is Managing Partner at Pontis Capital, an Austrian venture capital company. He has 10 years of experience as an investment manager, overseeing the whole investment life-cycle, from deal acquisition through active management of portfolio companies to financing and implementation of the exit strategy.
Harald Schuerz is CEO of Wiener Wachstumsfonds, an Austrian venture capital fund focusing on innovative, fast growing companies. Before joining Athena, he held executive positions at leading Austrian banks where he was responsible for venture capital investments and international financing.
About EUCODIS Bioscience
EUCODIS Bioscience provides enzymes to the chemical, health care, and other industries, and offers custom-engineering and custom-manufacturing services.
Customers use EUCODIS Bioscience’ enzymes and services to make their manufacturing processes more efficient and cleaner and to introduce products with superior properties. The Company’s technology of in vivo-recombination is a proven tool for the directed evolution of enzymes that perform to customers’ specific requirements.
Enzymes are proteins that catalyze highly specific chemical reactions, offering a safer, cleaner, and competitive alternative to traditional chemistry. They are at the center of industrial, or “white” biotechnology, a fast growing industry segment with sales in excess of EUR100 billion.
Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with a subsidiary in Germany.
For more information, please visit www.eucodisbioscience.com
Company contact EUCODIS Bioscience:
Thomas Fischer, MBA
CEO
EUCODIS Bioscience
Campus Vienna Biocenter II
Viehmarktgasse 2 a/ 2 OG
A-1030 Vienna
AUSTRIA
+ 43-1-8900804
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Media contact EUCODIS Bioscience:
Frank Butschbacher
Investor Relations & Communications
www.butschbacher.net
+43-650-7844940
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
|
Launch of LacBuster™ for Broadest Spectrum of Beta-Lactam Antibiotics |
|
Vienna, Europe, June 23, 2010 – EUCODIS Bioscience, a developer and manufacturer of customized enzymes today announced that it has launched a high-performance beta-lactamase designed to inactivate a broad range of beta-lactam antibiotics. EUCODIS Bioscience is marketing the product under the LacBuster™ brand.
Beta-lactamases are enzymes that inactivate beta-lactam antibiotics, hydrolyzing the beta-lactam ring, a molecular structure common to these drugs. This property makes beta lactamases an important tool in the manufacture of beta-lactam antibiotics, where they are used for sterility testing of bulk products. Within the USD 25 billion antibiotics market, beta-lactam antibiotics are the most widely prescribed group of drugs. Beta-lactamase enzymes are also used by the diagnostics industry, and in other areas.
“Our LacBuster™ beta-lactamase addresses the needs of leading antibiotics manufacturers, as it inactivates all relevant beta-lactam antibiotics, including penicillins, cephalosporins up to the 5th generation, and carbapenems, and shows an activity significantly higher than that of other products currently in the market”, said Bhupinder Hundle, Senior Vice President Marketing & Sales, EUCODIS Bioscience.
“The launch of a product that provides a better performance than previously available in the market demonstrates that we are deeply committed to helping pharmaceutical manufacturers and drug developers keeping their competitive edge”, said Thomas Fischer, CEO EUCODIS Bioscience. “At the same time, demand from the broader chemical industry is gaining momentum. With our enzyme products as well as our custom-engineering and manufacturing services we have been making strong inroads in areas such as specialty chemicals, cosmetics, animal feeds, as well as high-value products from biomass.“
About EUCODIS Bioscience
EUCODIS Bioscience provides enzymes to the chemical, health care, and other industries, and offers custom-engineering and custom-manufacturing services.
Customers use EUCODIS Bioscience’ enzymes and services to make their manufacturing processes more efficient and cleaner and to introduce products with superior properties. The Company’s technology of in vivo-recombination is a proven tool for the directed evolution of enzymes that perform to customers’ specific requirements.
Enzymes are proteins that catalyze highly specific chemical reactions, offering a safer, cleaner, and competitive alternative to traditional chemistry. They are at the center of industrial, or “white” biotechnology, a fast growing industry segment with sales in excess of EUR100 billion.
Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with a subsidiary in Germany.
For more information, please visit www.eucodisbioscience.com
Company contact EUCODIS Bioscience:
Thomas Fischer, MBA
CEO
EUCODIS Bioscience
Campus Vienna Biocenter II
Viehmarktgasse 2 a/ 2 OG
A-1030 Vienna
AUSTRIA
+ 43-1-8900804
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Media contact EUCODIS Bioscience:
Frank Butschbacher
Investor Relations & Communications
www.butschbacher.net
+43-650-7844940
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
|
Collaboration with Martin-Luther-University, Halle, Germany |
|
|
Collaboration with Martin-Luther-University Halle, Germany
Vienna, Europe, April 27, 2010 – EUCODIS Bioscience, a developer and manufacturer of customized enzymes, and Martin-Luther-University Halle-Wittenberg, Germany, (MLU), today announced a collaboration agreement for the characterization of novel lipases, phospholipases, and other enzymes that EUCODIS Bioscience is marketing or has under development.
“Given the breadth of potential uses of our enzymes, we would like to provide our customers with comprehensive analytical data on the characteristics of each enzyme in a corresponding range of environments”, said Thomas Fischer, CEO of EUCODIS Bioscience, commenting on the collaboration.
“We are extremely pleased that the collaboration with MLU gives us access to the extensive scientific experience and state-of-the-art instrumentation in enzyme research and protein analysis that Professor Bordusa and his team have built at the Institute of Biochemistry and Biotechnology. The Institute will serve as a ‘center of excellence” for the extensive characterization of our enzymes, and the data generated will be of substantial value to our customers in the short term.”
“We are excited about the opportunity to collaborate with EUCODIS Bioscience as an industry partner”, said Prof. Frank Bordusa, Head of the Department Natural Materials Biochemistry of the Institute of Biochemistry and Biotechnology, Martin-Luther-University Halle-Wittenberg, Germany. “Lipases are the most versatile class of commercial enzymes. A thorough characterization of these enzyme in relation to a diverse range of potential substrates and processes is important to industrial users, and scientifically challenging. Our collaboration with an industrial enzyme developer also has the potential to generate further projects of commercial value.”
Industrial enzymes are used in extremely diverse applications. Lipases are part of the formulations of laundry detergents, moisturizing cosmetics, bakery mixes, or animal feeds, and enable industrial processes such as the extraction and processing of vegetable oils, or the production of fine chemicals from biomass in a biorefinery, among many other applications.
About MLU’s Institute of Biochemistry and Biotechnology
The Institute of Biochemistry and Biotechnology of the Martin-Luther-University Halle-Wittenberg is one of the most successful institutes of the university in terms of the recruitment of third-party funds. Currently, research covered by third-party funds includes several Collaborative and Interdisciplinary Research Centers, DFG research groups and activities within several DFG Priority Programs, as well as the application-oriented ProNet-T3 network, which has recently been funded with EUR 11 million by the German Ministry of Science and Education.
The Department Natural Materials Biochemistry is involved in a number of the aforementioned activities and has long-term experience in the use of hydrolases as biocatalysts for chemical applications. The main field of interest covers the optimization of these enzymes by rational and evolutionary protein engineering including the identification of new enzymes for semisynthesis.
For details on MLU’s Institute of Biochemistry and Biotechnology please visit http://www.biochemtech.uni-halle.de/
About EUCODIS Bioscience
EUCODIS Bioscience develops and customizes enzymes for the chemical, health care, and other industries.
Customers use EUCODIS Bioscience’ enzymes to make their manufacturing processes more efficient and cleaner, and to introduce products with superior properties. The Company’s technology of in vivo-recombination is a proven tool for the development of enzymes that perform to customers’ specific requirements.
Enzymes are biological catalysts. They are at the center of industrial, or “white” biotechnology, a fast growing industry segment with sales in excess of EUR100 billion.
Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with a subsidiary in Germany.
For more information, please visit www.eucodisbioscience.com
Company contact EUCODIS Bioscience:
Thomas Fischer, MBA
CEO
EUCODIS Bioscience
Campus Vienna Biocenter II
Viehmarktgasse 2 a/ 2 OG
A-1030 Vienna
AUSTRIA
+ 43-1-8900804
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Media contact EUCODIS Bioscience:
Frank Butschbacher
Investor Relations & Communications
www.butschbacher.net
+43-650-7844940
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
|
Launch of Phospholipases Expands Enzyme Portfolio |
|
Vienna, Europe, March 9, 2010 – EUCODIS Bioscience, a company providing customized enzymes to the pharmaceutical, chemical, and other industries, announced today that it has launched a panel of phospholipases, adding a new enzyme family to its product portfolio.
Phospholipases are a group of enzymes that are widely used in the industrial processing of natural fats and oils, such as in the food and beverage industries, in the cosmetics industry, and in the manufacturing of bioproducts from renewable resources (biomass). The market for phospholipases is estimated at EUR 40 million.
In 2009, EUCODIS Bioscience has launched several enzyme products, including a library of currently 20 novel lipases and beta-lactamases
Commenting on the launch of a new product group, Thomas Fischer, CEO of EUCODIS Bioscience, said: “In adding new enzymes to our product portfolio, we continue to execute our customer-focused strategy: We offer novel enzymes with promising properties to a broad range of industries, we manufacture commercial quantities according to market demand, and we engineer enzymes to customers’ specific needs. Feedback from the market is an impressive confirmation of this strategy, with our order book filling steadily“.
About EUCODIS Bioscience
EUCODIS Bioscience GmbH develops, customizes, manufactures, and markets industrial enzymes.
EUCODIS Bioscience’ products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.
The Company offers a broad portfolio of novel enzymes, including lipases, phospholipases, and beta-lactamases.
Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with a subsidiary in Germany.
For more information, please visit www.eucodisbioscience.com
Company contact EUCODIS Bioscience:
Thomas Fischer, MBA
CEO
EUCODIS Bioscience
Campus Vienna Biocenter II
Viehmarktgasse 2 a/ 2 OG
A-1030 Vienna
AUSTRIA
+43 1 8900804
Media contact EUCODIS Bioscience:
Frank Butschbacher
Investor Relations & Communications
www.butschbacher.net
+43 650 7844940 |
|
EUR 2 Million Cash Injection to Enlarge Portfolio, Develop Markets |
|
Vienna, Europe, February 3, 2010 - EUCODIS Bioscience, a company providing customized enzymes to the pharmaceutical, chemical, and other industries, announced today that it has received a cash injection of EUR 2 million from existing shareholders.
The Company will use these funds to swiftly add new enzyme families to its product portfolio and to accelerate the development of international markets. At the same time, EUCODIS Bioscience is expanding its manufacturing capacity in pace with growing customer demand for its novel enzymes. Commenting on the capital injection Thomas Fischer, CEO of EUCODIS Bioscience, said: "Following several product launches in 2009 and the recent expansion of our lipases family to 20 enzymes we continue to build our order book. Accordingly, our revenues will finance a good part of our expenses and investments this year."
|
|
Read more...
|
|
EUCODIS Bioscience Appoints Thomas Fischer as New CEO |
|
Enzyme Developer to Strengthen Commercial Focus - Outgoing CEO Dr. Pandjaitan to Acquire Majority Stake in Former Research Subsidiary in Management Buy-In
Vienna, Europe, December 7, 2009 - EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry, announced today that it has appointed Mr Thomas Fischer, currently CFO, as new CEO of the Company. Going forward, EUCODIS Bioscience' sole focus will be to provide high-performance enzymes to customers, capitalizing on the Company's experience in commercial enzyme development and on its proven technology of 'in vivo recombination'.
|
|
Read more...
|
|
EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus |
|
|
Vienna, Europe, November 6, 2009 - EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry announced today that it has entered into a research agreement with Bio Sidus, the leading biopharmaceutical company in Latin America.
|
|
Read more...
|
|
